We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene (s) of Candida spp. and Aspergillus spp. …

Ibrexafungerp (MK 3118) 是一种具有口服活性的 β-1,3-葡聚糖 合成抑制剂，具有有效的抗真菌活性。 Ibrexafungerp 可用于研究念珠菌 (Candida)和曲霉菌 (Aspergillus) 感染。 * Please …

Fixed stainless steel bezel set with white Swarovski crystals. Mother of pearl dial with silver-tone hands and stick hour markers. Quartz movement. Scratch resistant mineral crystal. Solid case …

MK-3118 (24 h of incubation and 50% EC) was active against all the species tested and displayed similar potency to caspofungin (using CLSI BMD) against C. albicans (MIC90, 1 and 2 mg/L, …

MK-3118, a glucan synthase inhibitor derived from enfumafungin, and comparator agents were tested against 71 Aspergillus spp., including itraconazole-resistant strains (MIC, ≥ 4 μg/ml), …

Ibrexafungerp 柠檬酸盐（MK-3118；SCY078；MK3118；SCY-078；Brexafemme）是 Ibrexafungerp 的柠檬酸盐，是一种 β-1,3-葡聚糖合成抑制剂，被批准作为治疗外阴阴道念珠菌 …

2015年1月27日 · Derivatives of enfumafungin are novel orally bioavailable glucan synthase inhibitors. We performed an in vivo pharmacodynamic (PD) evaluation with a novel …

Ibrexafungerp (originally known as MK-3118) is a semi-synthetic, orally bioavailable antifungal derivative of the echinocandin enfumafungin [1, 2]. Echinocandins are...

MK-3118 is an orally active, semisynthetic derivative of the natural product enfumafungin with in vitro and in vivo activity against Aspergillus spp. ( 18 – 22 ). MK-3118 and other derivatives of …